3-(4-Methylphenyl)-1,2,4-oxadiazol-5-essigsaeure | 64634-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-Methylphenyl)-1,2,4-oxadiazol-5-essigsaeure
• 英文别名: (3-p-tolyl-[1,2,4]oxadiazol-5-yl)-acetic acid；(3-p-Tolyl-[1,2,4]oxadiazol-5-yl)-acetic acid；2-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]acetic acid
• CAS: 64634-29-3
• 化学式: C₁₁H₁₀N₂O₃
• mdl: MFCD10035200
• 分子量: 218.212
• InChiKey: DTJLKFLJJUQICD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(4-Methylphenyl)-1,2,4-oxadiazol-5-essigsaeure 、 7-氨基头孢烷酸 生成 3-<(Acetyloxy)methyl>-7-<1,2,4-oxadiazol-5-yl-acetyl>-amino-3-cephem-4-carbon-saeure
  参考文献：
  名称：

  Malabarba; Cavalleri; Berti, Farmaco, Edizione Scientifica, 1977, vol. 32, # 9, p. 650 - 664

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 2-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)acetate 在 氢氧化钾 作用下， 生成 3-(4-Methylphenyl)-1,2,4-oxadiazol-5-essigsaeure
  参考文献：
  名称：

  Malabarba; Cavalleri; Berti, Farmaco, Edizione Scientifica, 1977, vol. 32, # 9, p. 650 - 664

  摘要：

  DOI：

文献信息

• Coumarin derivatives, their preparation and their use as optical
  申请人：Produits Chimiques Ugine Kuhlmann

  公开号：US03994907A1

  公开（公告）日：1976-11-30

  Coumarin of the formula: ##SPC1## In which R.sub.1 represents an alkyl group having 1 to 5 carbon atoms, and either unsubstituted or substituted by a non-ionic and non-chromophoric group, R.sub.2 represents a benzene, styryl or heterocyclic residue such residue being unsubstituted or substituted by one or two non-ionic and non-chromophoric groups; process for the preparation of a coumarin of the above formula which comprises reacting an orthohydroxy-benzaldehyde of formula (II) upon an acid of formula (III) or one of its functional derivatives: ##SPC2## Wherein R.sub.1 and R.sub.2 have the same definitions as in claim 1; process for the fluorescent brightening of fibrous material of synthetic origin which comprises treating the material with a coumarin of the above formula; fluorescent brightening composition containing a coumarin of the above formula and a dispersing agent resulting from the condensation of naphthalene-sulphonic acids with formaldehyde in the presence of or absence of phenol compounds, said dispersing agent comprising 30% to 50% monosulphonated condensates, 30% to 50% disulphonated condensates and 10% to 40% trisulphonated or higher polysulphonated condensates; fibres of synthetic origin treated with a coumarin of the above formula or with a brightening composition as set out above.

  公式为：##SPC1## 其中R.sub.1表示1至5个碳原子的烷基，可以是未取代的或被非离子和非色团基团取代的；R.sub.2表示苯基，亚基或杂环残基，该残基可以是未取代的或被一或两个非离子和非色团基团取代的；制备上述公式的香豆素的过程包括将公式（II）的邻羟基苯甲醛与公式（III）或其官能衍生物之一发生反应：##SPC2## 其中R.sub.1和R.sub.2的定义与权利要求1中相同；用上述公式的香豆素处理合成纤维材料的荧光增白过程；荧光增白组合物包括上述公式的香豆素和萘磺酸与甲醛在酚类化合物的存在或不存在下缩聚而成的分散剂，所述分散剂包括30％至50％的单磺酸缩聚物，30％至50％的双磺酸缩聚物和10％至40％的三磺酸或更高磺酸缩聚物；用上述公式的香豆素或上述增白组合物处理的合成纤维。
• Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat Model
  作者：Concettina La Motta、Stefania Sartini、Silvia Salerno、Francesca Simorini、Sabrina Taliani、Anna Maria Marini、Federico Da Settimo、Luciana Marinelli、Vittorio Limongelli、Ettore Novellino

  DOI：10.1021/jm701613h

  日期：2008.6.1

  A number of 1,2,4-oxadiazol-5-yl-acetic acids and oxazol-4-yl-acetic acids were synthesized and tested for their ability to inhibit aldose reductase (ALR2). The oxadiazole derivatives, 7c, 7f, 7i, and 8h, 8i, proved to be the most active compounds, exhibiting inhibitory levels in the submicromolar range. In this series, the phenyl group turned out to be the preferred substitution pattern, as its lengthening to a benzyl moiety determined a general reduction of the inhibitory potency. The lead compound, 2-[3-(4-methoxyphenyl)1,2,4-oxadiazol-5-yl] acetic acid, 7c, showed an excellent in vivo activity, proving to prevent cataract development in severely galactosemic rats when administered as an eye-drop solution in the precorneal region of the animals. Computational studies on the ALR2 inhibitors were performed to rationalize the structure-activity relationships observed and to provide the basis for further structure-guided design of novel ALR2 inhibitors.
• US3994907A
  申请人：——

  公开号：US3994907A

  公开（公告）日：1976-11-30